Antibody Clinical Development Licensing Pharma Companies 
pharmaphorum
DECEMBER 21, 2021
Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.
pharmaphorum
JUNE 16, 2021
California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Exchange (NYSE) that will be used in part to fund clinical development of ARX-788, its HER2-targeting antibody drug conjugate (ADC). billion upfront, when it licensed the ADC from Daiichi Sankyo in 2019.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Delveinsight
AUGUST 2, 2020
The company has also signed a licensing agreement with Ono Pharmaceutical , a Japanese pharma company, transferring exclusive rights to develop and commercialise anamorelin in Japan, South Korea, and Taiwan. Cancer Cachexia Pipeline. Apart from the products as mentioned earlier, Tetra Bio?
Drug Discovery World
JULY 22, 2024
In addition to BSB-1001, BlueSphere has also discovered and nominated three additional miHA-targeting TCRs for clinical development, all for use in the same clinical setting as BSB-1001. A few companies fully support cellular therapies, while others have consciously shied away.
Drug Discovery World
OCTOBER 4, 2022
Oligomerix’s portfolio of compounds is expected to provide a potentially lower-cost treatment alternative and/or complement to the newly emerging high-cost therapeutic options such as the monoclonal antibody products. Several of the large pharma companies have recently re-entered the dementia field. With its recent award of $3.35
pharmaphorum
SEPTEMBER 8, 2022
It is a similar approach to that of another form of oncology treatment that is also experiencing a surge of interest, antibody-drug conjugates (ADCs). Big pharma has already noted its interest in the area, as seen in Novartis’ investments. The reason for the shutdown was due to potential discovery of quality issues at its plants.
Drug Discovery World
JULY 2, 2024
So, in this way there is a cross fertilisation from the bigger companies to newer ones. Start-ups will also take drug candidates from the pharma companies that are not getting attention for one reason or another and develop those into viable commercial products.” References [link] [link].
Expert insights. Personalized for you.
95 
Let's personalize your content